ArticleBMC infectious diseases2025
Acute encephalitis syndrome and Japanese encephalitis in India: insights from a nationally representative laboratory surveillance network, 2014-2023.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAcute Encephalitis Syndrome (AES) is a critical public health issue, contributing significantly to morbidity and mortality in India, particularly among children. Despite ongoing vaccination efforts, Japanese Encephalitis (JE) remains a major cause of AES. This study analyzes the epidemiology of AES and JE in India from 2014 to 2023, using data from the Virus Research and Diagnostic Laboratory Network (VRDLN).
methodsA cross-sectional analysis was conducted on AES cases reported by 159 VRDLN laboratories between 2014 and 2023. Standardized diagnostic tests such as polymerase chain reaction were used to identify causative pathogens, including JE virus. All the labs in the network followed BSL-2 standards. Descriptive analyses were performed on AES cases by year, etiology, and demographic factors. JE cases were further analyzed for geographic distribution, age, sex, and clinical characteristics.
resultsOver the study period, 124,890 AES cases were reported, with 16.3% testing positive for at least one pathogen, including 10% confirmed as JE. The highest JE positivity was observed in the northeastern states. An increasing trend in the number of cases tested and JE detections was noted, alongside a shift in the age distribution towards younger populations. The median (IQR) annual test positivity for JEV among tested was 16.2% (14.5%, 18.4%).
conclusionsThe VRDLN has substantially enhanced India's capacity to diagnose and monitor AES and JE. Despite progress, JE transmission persists, particularly in endemic regions, posing significant public health challenges. Strengthened surveillance, improved diagnostic coverage, and integrated pathogen testing are essential for effective interventions. Targeted strategies and sustained public health efforts are critical to reducing the burden of AES and JE in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.